[18F]PF-06445974 to Image PDE4B in Major Depressive Disorder Using PET
Status:
Recruiting
Trial end date:
2025-04-11
Target enrollment:
Participant gender:
Summary
Study Description:
This study will examine whether phosphodiesterase 4B (PDE4B) can be accurately quantified in
the human brain and whether it is reduced in the brain of individuals with major depressive
disorder (MDD).
Objectives:
Primary Objective:
To determine whether PDE4B is reduced in the brains of individuals with MDD experiencing a
major depressive episode (MDE).
Secondary Objectives:
To determine the optimal length of scanning and the retest variability and reliability of
[18F]PF-06445974, and whether PDE4B binding correlates with clinical rating scales.
Endpoints:
Primary Endpoint: measurement of PDE4B density (distribution volume VT) in the brains of
individuals with MDD compared to healthy volunteers
Secondary endpoints:
1. To determine the optimal length for PDE4B scans with [18F]PF-06445974 PET scans in
healthy volunteers
2. To measure whole-brain VT of PDE4B in a retest setting.
3. To assess the relationship between clinical rating scales and PDE4B binding